PCRX Stock Price, Chart, Stats & News

Pacira BioSciences, Inc.
Save
893.30M
Market cap
174.69x
Current P/E
7.61x
Forward P/E
PCRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 77.41% |
Operating margin | 2.76% |
Pretax margin | 2.32% |
Net margin | 0.97% |
Effective tax rate | 58.31% |
ROA | 0.56% |
ROE | 0.95% |
D/E | 0.66x |
Interest coverage ratio | 1.19x |
PCRX valuation
P/E | 174.69x |
P/S | 1.36x |
P/B | 1.40x |
P/CF | 6.40x |
P/FCF | 7.20x |
P/OCF | 6.40x |
PEG | -2.05x |
EV multiple | 5.65x |
About
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves.
Similar securities
Based on sector and market capitalization
Report issue











